BC
RGLS

Boxer Capital’s Regulus Therapeutics RGLS Stock Holding History

Boxer Capital’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,148
Closed -$4.03M – 25
2018
Q3 		$4.03M Hold
14,148
– – 0.45% 20
2018
Q2 		$1.12M Hold
14,148
– – 0.13% 25
2018
Q1 		$1.22M Sell
14,148
-4,167
-23% -$558K 0.13% 32
2017
Q4 		$2.29M Hold
18,315
– – 0.42% 24
2017
Q3 		$2.75M Buy
+18,315
New +$2.3M 0.63% 21

Other funds holding RGLS

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Boxer Capital's RGLS Position: Q4 2018 in Review

Boxer Capital sold out of Regulus Therapeutics (RGLS) in Q4 2018, closing a stake of 14,148 shares — an estimated $4.03M sold.

Boxer Capital first reported a position in RGLS in Q3 2017 and held it in 5 quarters. The position peaked at $4.03M in Q3 2018. 27 funds tracked by Wall St. Rank hold RGLS as of Q4 2018.

  • Boxer Capital reported no remaining Regulus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Boxer Capital sold 14,148 Regulus Therapeutics shares in Q4 2018, an estimated $4.03M.
  • Boxer Capital first reported a position in Regulus Therapeutics in Q3 2017 and held it in 5 quarters.
  • Boxer Capital's Regulus Therapeutics position peaked at $4.03M in Q3 2018.
  • 27 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2018.

Based on Boxer Capital's 13F filing for Q4 2018, filed 14 Feb 2019.